DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer
29 oct. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...
Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and a New President of DRGT Research
21 oct. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell...
DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)
18 sept. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New...
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
15 juil. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
10 juin 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...
DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development
05 févr. 2019 03h22 HE
|
Druggability Technologies Holdings Ltd
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named...
Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer
06 déc. 2018 03h29 HE
|
Druggability Technologies Holdings Ltd
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Druggability Technologies USA today announced that Dr. John E. Friend II has been named as Chief Medical Officer. Druggability Technologies USA has been...
Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99
02 mai 2018 05h29 HE
|
Druggability Technologies Holdings Ltd
MALTA, May 02, 2018 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for...
DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform
05 oct. 2017 05h28 HE
|
Druggability Technologies Holdings Ltd
MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®),...
DRGT's novel Celecoxib composition - opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market
19 déc. 2016 07h48 HE
|
Druggability Technologies
SWATAR, MALTA--(Marketwired - Dec. 19, 2016) - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions...